EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD

Go back to EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD
(NASDAQ: EYPT) Delayed: 0.43 --0 (-0%)
Previous Close $0.43    52 Week High $ 
Open $0.43    52 Week Low $ 
Day High $0.44    P/E N/A 
Day Low $0.42    EPS $ 
Volume 12,495,490